Use of Infliximab or Adalimumab in Biologic-Naive Patients With Inflammatory Bowel Disease: Study of Patient Reported Outcomes in IBD Partners

被引：0
|
作者：
Weaver, Kimberly [1 ]
Curtis, Jeffrey [2 ]
Beukelman, Tim [2 ]
Zhang, Xian [1 ]
Kappelman, Michael [1 ]
Long, Millie [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2019年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P105
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [1] Vedolizumab Decreases Utilization of Healthcare Resources in Biologic-naive Inflammatory Bowel Disease (IBD) Patients
    Kassim, Olufemi
    Micic, Dejan
    Christensen, Britt
    Lissoos, Trevor
    Luo, Michelle
    Null, Kyle D.
    Cohen, Russell
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S334 - S335
  • [2] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
  • [3] Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
    Smith, Joshua T.
    Velayos, Fernando S.
    Niu, Fang
    Liu, Vincent
    Delate, Thomas
    Pola, Suresh
    Le, Kim
    Hui, Rita L.
    CROHNS & COLITIS 360, 2021, 3 (03)
  • [4] Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease
    Patel, Haridarshan
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    CROHNS & COLITIS 360, 2019, 1 (02)
  • [5] Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naive patients with inflammatory bowel disease
    Latremouille-Viau, D.
    Burne, R.
    Shi, S.
    Adsul, S.
    Patel, H.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S295 - S296
  • [6] Comparison of long-term outcomes of infliximab and adalimumab in biologic-naive patients with ulcerative colitis
    Durak, M. B.
    Baspinar, B.
    Guven, I. E.
    Kivrakoglu, F.
    Kilic, V.
    Kosar, K.
    Erdogan, C.
    Yuksel, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I547 - I547
  • [7] COMPARISONS OF HOLISTIC PATIENT-REPORTED OUTCOMES BY BIOLOGIC DRUG CLASS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY IN IBD PARTNERS
    Long, Millie
    Zhang, Xian
    Chen, Wenli
    Lissoos, Trevor
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S23 - S24
  • [8] Comparison of long-term outcomes of infliximab and adalimumab in biologic-naive patients with ulcerative colitis
    Durak, M. B.
    Baspinar, B.
    Guven, I. E.
    Kivrakoglu, F.
    Kilic, V.
    Kosar, K.
    Erdogan, C.
    Yuksel, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I547 - I547
  • [9] COMPARISONS OF HOLISTIC PATIENT-REPORTED OUTCOMES BY BIOLOGIC DRUG CLASS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY IN IBD PARTNERS
    Long, Millie
    Zhang, Xian
    Chen, Wenli
    Lissoos, Trevor
    GASTROENTEROLOGY, 2020, 158 (03) : S38 - S38
  • [10] USE OF DIFFERENT STATISTICAL APPROACHES TO COMPARE REAL-WORLD OUTCOMES ASSOCIATED WITH VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, D.
    Burne, R.
    Shi, S.
    Patel, H.
    VALUE IN HEALTH, 2019, 22 : S178 - S178
12345